Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis

Area of Science:

• Biomedical Engineering
• Oncology
• Nanotechnology

Background:

• Triple-negative breast cancer (TNBC) presents significant challenges in distinguishing malignant from non-neoplastic cells.
• Effective targeting of both primary tumors and metastatic lesions in TNBC remains a critical unmet need.

Purpose of the Study:

• To develop a novel complementary targeting strategy for enhanced TNBC treatment.
• To engineer dual complementary liposomes (DCLs) for precise recognition of TNBC cell surface markers.

Main Methods:

• Screening of cancer cell surface markers to identify optimal targets for TNBC.
• Engineering DCLs to complement the molecular ratio and organization of intercellular adhesion molecule-1 (ICAM1) and epithelial growth factor receptor (EGFR) on TNBC cells.
• In vitro and in vivo evaluation of DCLs in orthotopic and lung metastasis models.

Main Results:

• DCLs demonstrated increased binding, enhanced cellular internalization, and reduced receptor signaling compared to single-targeting liposomes.
• DCLs exhibited significantly improved tumor targeting activity in preclinical models.
• Substantially enhanced antitumor efficacy was observed with DCLs in both primary and metastatic TNBC models.

Conclusions:

• DCLs represent a promising platform technology for personalized nanomedicine in TNBC treatment.
• The complementary targeting strategy offers a novel approach for improving the specificity and efficacy of cancer therapies.
• This approach has the potential to improve outcomes for patients with TNBC by targeting both primary and metastatic disease.